The endocannabinoid system and NGF are involved in the mechanism of action of resveratrol: a multi-target nutraceutical with therapeutic potential in neuropsychiatric disorders

[1]  M. Ichikawa,et al.  Corrigendum: Dynamics of microdroplets over the surface of hot water , 2015, Scientific Reports.

[2]  A. Micera,et al.  Nerve Growth Factor: A Focus on Neuroscience and Therapy , 2015, Current neuropharmacology.

[3]  R. Mensink,et al.  Resveratrol Does Not Influence Metabolic Risk Markers Related to Cardiovascular Health in Overweight and Slightly Obese Subjects: A Randomized, Placebo-Controlled Crossover Trial , 2015, PloS one.

[4]  A. Shetty,et al.  Resveratrol Prevents Age-Related Memory and Mood Dysfunction with Increased Hippocampal Neurogenesis and Microvasculature, and Reduced Glial Activation , 2015, Scientific Reports.

[5]  K. Klein,et al.  Resveratrol does not benefit patients with nonalcoholic fatty liver disease. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[6]  L. Hurley,et al.  Antidepressant effects of resveratrol in an animal model of depression , 2014, Behavioural Brain Research.

[7]  R. Ahmed,et al.  Antidepressant-like effect of resveratrol in a subchronic model of depression , 2014 .

[8]  L. Saha,et al.  Understanding the anti-kindling role and its mechanism of Resveratrol in Pentylenetetrazole induced-kindling in a rat model , 2014, Pharmacology Biochemistry and Behavior.

[9]  Jun Li,et al.  Antidepressant-like effect of resveratrol: Involvement of antioxidant effect and peripheral regulation on HPA axis , 2013, Pharmacology Biochemistry and Behavior.

[10]  Xueer Wang,et al.  Antidepressant-like activity of resveratrol treatment in the forced swim test and tail suspension test in mice: The HPA axis, BDNF expression and phosphorylation of ERK , 2013, Pharmacology Biochemistry and Behavior.

[11]  M. Garcia-Conesa,et al.  Resveratrol and Clinical Trials: The Crossroad from In Vitro Studies to Human Evidence , 2013, Current pharmaceutical design.

[12]  P. Hassanzadeh,et al.  Implication of NGF and endocannabinoid signaling in the mechanism of action of sesamol: a multi-target natural compound with therapeutic potential , 2013, Psychopharmacology.

[13]  J. O'Donnell,et al.  Antidepressant-like effect of trans-resveratrol in chronic stress model: behavioral and neurochemical evidences. , 2013, Journal of psychiatric research.

[14]  K. Schechtman,et al.  Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance. , 2012, Cell metabolism.

[15]  P. Hassanzadeh,et al.  Cannabinoid CB1 Receptors Mediate the Gastroprotective Effect of Neurotensin , 2012, Iranian journal of basic medical sciences.

[16]  J. Auwerx,et al.  The journey of resveratrol from yeast to human , 2012, Aging.

[17]  R. McLaughlin,et al.  Cannabinoids and emotionality: a neuroanatomical perspective , 2012, Neuroscience.

[18]  Wei Zhang,et al.  Resveratrol Inhibits Inflammatory Responses via the Mammalian Target of Rapamycin Signaling Pathway in Cultured LPS-Stimulated Microglial Cells , 2012, PloS one.

[19]  P. Hassanzadeh,et al.  The CB1 Receptor-Mediated Endocannabinoid Signaling and NGF: The Novel Targets of Curcumin , 2012, Neurochemical Research.

[20]  P. Currie,et al.  The cannabinoid receptor CB1 inverse agonist AM251 potentiates the anxiogenic activity of urocortin I in the basolateral amygdala , 2012, Neuropharmacology.

[21]  M. Reith,et al.  The novel trisubstituted pyran derivative D-142 has triple monoamine reuptake inhibitory activity and exerts potent antidepressant-like activity in rodents. , 2011, European journal of pharmacology.

[22]  P. Hassanzadeh,et al.  Involvement of the neurotrophin and cannabinoid systems in the mechanisms of action of neurokinin receptor antagonists , 2011, European Neuropsychopharmacology.

[23]  P. Hassanzadeh,et al.  The Role of the Endocannabinoids in Suppression of the Hypothalamic-pituitary-adrenal Axis Activity by Doxepin , 2011, Iranian journal of basic medical sciences.

[24]  Stuart Maudsley,et al.  Amitriptyline-Mediated Cognitive Enhancement in Aged 3×Tg Alzheimer's Disease Mice Is Associated with Neurogenesis and Neurotrophic Activity , 2011, PloS one.

[25]  P. Hassanzadeh,et al.  The cannabinergic system is implicated in the upregulation of central NGF protein by psychotropic drugs , 2011, Psychopharmacology.

[26]  Karen Brown,et al.  Clinical trials of resveratrol , 2011, Annals of the New York Academy of Sciences.

[27]  P. Hassanzadeh.  The endocannabinoid system: critical for the neurotrophic action of psychotropic drugs , 2010 .

[28]  Ying Xu,et al.  Antidepressant-like effect of trans-resveratrol: Involvement of serotonin and noradrenaline system , 2010, European Neuropsychopharmacology.

[29]  R. Abalo,et al.  The cannabinoid antagonist SR144528 enhances the acute effect of WIN 55,212‐2 on gastrointestinal motility in the rat , 2010, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[30]  Á. Simonyi,et al.  Resveratrol as a Therapeutic Agent for Neurodegenerative Diseases , 2010, Molecular Neurobiology.

[31]  Lutz Hein,et al.  α2-Adrenoceptor Blockade Accelerates the Neurogenic, Neurotrophic, and Behavioral Effects of Chronic Antidepressant Treatment , 2010, The Journal of Neuroscience.

[32]  T. Sejnowski,et al.  NGF Is Essential for Hippocampal Plasticity and Learning , 2009, The Journal of Neuroscience.

[33]  Gelin Xu,et al.  Combination therapy with intranasal NGF and electroacupuncture enhanced cell proliferation and survival in rats after stroke , 2009, Neurological research.

[34]  P. Blier.  Generic Substitution for Psychotropic Drugs , 2009, CNS Spectrums.

[35]  L. Ereshefsky,et al.  Drug-drug interactions with the use of psychotropic medications. Interview by Diane M. Sloan. , 2009, CNS spectrums.

[36]  K. Ye,et al.  Amitriptyline is a TrkA and TrkB receptor agonist that promotes TrkA/TrkB heterodimerization and has potent neurotrophic activity. , 2009, Chemistry & biology.

[37]  M. Martinoli,et al.  Protective Effects of Resveratrol and Quercetin Against MPP+ -Induced Oxidative Stress Act by Modulating Markers of Apoptotic Death in Dopaminergic Neurons , 2009, Cellular and Molecular Neurobiology.

[38]  A. Duranti,et al.  Endocannabinoids in the treatment of mood disorders: evidence from animal models. , 2009, Current pharmaceutical design.

[39]  Á. Díaz,et al.  Altered CB1 receptor‐signaling in prefrontal cortex from an animal model of depression is reversed by chronic fluoxetine , 2009, Journal of neurochemistry.

[40]  Enguo Fan,et al.  Beneficial effects of resveratrol on atherosclerosis. , 2008, Journal of medicinal food.

[41]  L. Pirola,et al.  Resveratrol: One molecule, many targets , 2008, IUBMB life.

[42]  M. Martinoli,et al.  Resveratrol and quercetin, two natural polyphenols, reduce apoptotic neuronal cell death induced by neuroinflammation , 2008, Journal of neuroscience research.

[43]  A. Jula,et al.  Favorable effects of berry consumption on platelet function, blood pressure, and HDL cholesterol. , 2008, The American journal of clinical nutrition.

[44]  J. Laugharne,et al.  Complementary and alternative medicine in the treatment of anxiety and depression , 2008, Current opinion in psychiatry.

[45]  JaneR . Taylor,et al.  Chronic Unpredictable Stress Decreases Cell Proliferation in the Cerebral Cortex of the Adult Rat , 2007, Biological Psychiatry.

[46]  M. López-Gallardo,et al.  Endocannabinoid System and Synaptic Plasticity: Implications for Emotional Responses , 2007, Neural plasticity.

[47]  H. Baumeister,et al.  Prevalence of mental disorders based on general population surveys , 2007, Social Psychiatry and Psychiatric Epidemiology.

[48]  C. Nemeroff.  The burden of severe depression: a review of diagnostic challenges and treatment alternatives. , 2007, Journal of psychiatric research.

[49]  H. Manji,et al.  Neurotrophic signaling cascades in the pathophysiology and treatment of bipolar disorder. , 2007, Current opinion in pharmacology.

[50]  E. Castrén,et al.  Role of neurotrophic factors in depression. , 2007, Current opinion in pharmacology.

[51]  R. Duman,et al.  Intracellular signaling pathways pave roads to recovery for mood disorders , 2007, Annals of medicine.

[52]  C. Koebnick,et al.  Serum resistin increases in a postprandial state during liquid meal challenge test in healthy human subjects , 2006, Journal of endocrinological investigation.

[53]  P. Pacher,et al.  The Endocannabinoid System as an Emerging Target of Pharmacotherapy , 2006, Pharmacological Reviews.

[54]  M. Sánchez-Hidalgo,et al.  The effects of resveratrol, a phytoalexin derived from red wines, on chronic inflammation induced in an experimentally induced colitis model , 2006, British journal of pharmacology.

[55]  Eric J. Nestler,et al.  New approaches to antidepressant drug discovery: beyond monoamines , 2006, Nature Reviews Neuroscience.

[56]  T. Cassano,et al.  Correction for Gobbi et al., Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[57]  M. Valenti,et al.  Effect of repeated systemic administration of selective inhibitors of endocannabinoid inactivation on rat brain endocannabinoid levels. , 2005, Biochemical pharmacology.

[58]  S. File,et al.  Endocannabinoid system and stress and anxiety responses , 2005, Pharmacology Biochemistry and Behavior.

[59]  V. Parikh,et al.  Differential effects of typical and atypical antipsychotics on nerve growth factor and choline acetyltransferase expression in the cortex and nucleus basalis of rats. , 2004, Journal of psychiatric research.

[60]  G. Marsicano,et al.  Involvement of brain‐derived neurotrophic factor in cannabinoid receptor‐dependent protection against excitotoxicity , 2004, The European journal of neuroscience.

[61]  Wenhua Zheng,et al.  Neuroprotective effects of resveratrol against β‐amyloid‐induced neurotoxicity in rat hippocampal neurons: involvement of protein kinase C , 2004, British journal of pharmacology.

[62]  E. Mufson,et al.  Nerve growth factor: structure, function and therapeutic implications for Alzheimer's disease. , 2003, Current drug targets. CNS and neurological disorders.

[63]  C. Hillard,et al.  Differential Regulation of the Endocannabinoids Anandamide and 2-Arachidonylglycerol within the Limbic Forebrain by Dopamine Receptor Activity , 2003, Journal of Pharmacology and Experimental Therapeutics.

[64]  F. Walsh,et al.  The FGF receptor uses the endocannabinoid signaling system to couple to an axonal growth response , 2003, The Journal of cell biology.

[65]  R. Gwinn,et al.  Time-dependent increase in basic fibroblast growth factor protein in limbic regions following electroshock seizures , 2002, Neuroscience.

[66]  T. Moriizumi,et al.  Role of nerve growth factor in the olfactory system , 2002, Microscopy research and technique.

[67]  R. Hellweg,et al.  Serotonergic lesion of median raphe nucleus alters nerve growth factor content and vulnerability of cholinergic septohippocampal neurons in rat , 2001, Brain Research.

[68]  E. Esposito,et al.  Acute administration of amitriptyline and mianserin increases dopamine release in the rat nucleus accumbens: possible involvement of serotonin2C receptors , 2000, Psychopharmacology.

[69]  L. Thal,et al.  Nerve Growth Factor (NGF) Augments Cortical and Hippocampal Cholinergic Functioning after p75NGF Receptor-Mediated Deafferentation But Impairs Inhibitory Avoidance and Induces Fear-Related Behaviors , 2000, The Journal of Neuroscience.

[70]  H. Homma,et al.  Liquid chromatographic-atmospheric pressure chemical ionization mass spectrometric determination of anandamide and its analogs in rat brain and peripheral tissues. , 1997, Journal of chromatography. B, Biomedical sciences and applications.

[71]  J. Conner,et al.  Nerve growth factor (NGF) content in adult rat brain tissues is several-fold higher than generally reported and is largely associated with sedimentable fractions , 1996, Brain Research.

[72]  M. Washburn,et al.  Nerve growth factor facilitates cholinergic neurotransmission between nucleus basalis and the amygdala in rat: an electrophysiological analysis , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[73]  P. Walson,et al.  Anticonvulsant tolerance to clonazepam in amygdala kindled rats: Clonazepam concentrations and benzodiazepine receptor binding , 1994, Neuropharmacology.

[74]  L. Buéno,et al.  Clonazepam-induced intestinal motor disturbances are linked to central nervous system release of cholecystokinin in rats. , 1993, European journal of pharmacology.

[75]  T. Ebendal.  Function and evolution in the NGF family and its receptors , 1992, Journal of neuroscience research.

[76]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[77]  J. Manzanares,et al.  CB1 receptor blockade decreases ethanol intake and associated neurochemical changes in fawn-hooded rats. , 2010, Alcoholism, clinical and experimental research.

[78]  P. Hassanzadeh,et al.  EFFECTS OF DIFFERENT PSYCHOTROPIC AGENTS ON THE CENTRAL NERVE GROWTH FACTOR PROTEIN , 2010 .

[79]  G. Marsicano,et al.  Neuromodulatory functions of the endocannabinoid system. , 2006, Journal of endocrinological investigation.

[80]  R. Hellweg,et al.  Subchronic treatment with lithium increases nerve growth factor content in distinct brain regions of adult rats , 2002, Molecular Psychiatry.

[81]  E. Huang,et al.  Neurotrophins: roles in neuronal development and function. , 2001, Annual review of neuroscience.

[82]  G. Paxinos,et al.  The Rat Brain in Stereotaxic Coordinates , 1983 .

[83]  B. Pitt.  Psychopharmacology , 1968, Mental Health.